• Vaccine Name: L. infantum SMT Protein Vaccine
• Target Pathogen: Leishmania infantum
• Target Disease: Infantile visceral leishmaniasis
• Vaccine Ontology ID: VO_0004066
• Type: Subunit vaccine
• Status: Research
• SMT gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001250
  • Description: 20 μg of MPL®-SE (GlaxoSmithKline Biologicals, Rixensant, Belgium) (Goto et al., 2007).
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Mice were immunized with 10 μg of rSMT plus 20 μg of MPL®-SE in a volume of 0.1 ml. Another group of mice was administrated with 10 μg of rSMT alone. Control groups received either saline or MPL®-SE alone. The mice were immunized subcutaneously three times at three weeks intervals in the right hind footpad and at the base of the tail (Goto et al., 2007).
• Challenge Protocol: Mice were challenged with L. infantum three weeks after the last immunization. 5 × 10^6 L. infantum promastigotes were suspended in Hank's balanced salt solution and injected i.v. into the tail vein of the mouse (Goto et al., 2007).
• Efficacy: Significant reduction of parasites was seen in mice immunized with rSMT plus MPL®-SE compared with those in saline or adjuvant alone groups. The immunized mice showed 43-fold and 55-fold reduction in the number of parasites in spleens, 111-fold and 117-fold reduction in livers compared with saline and adjuvant alone groups, respectively (Goto et al., 2007).